Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT01967069 Completed - Psoriasis Clinical Trials

A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis

Start date: November 2013
Phase: Phase 3
Study type: Interventional

The objectives of this study are to compare the efficacy and safety of DFD01 Spray to Vehicle Spray for topical treatment of moderate plaque psoriasis

NCT ID: NCT01964443 Completed - Psoriasis Clinical Trials

Clinical Assessment and Psychosocial Impact of Psoriasis

EPIDEPSO
Start date: September 2013
Phase: Phase 4
Study type: Observational

The purpose of this study is to explore the impact of plaque psoriasis on the different dimensions of patient life including psychological disorders, different types of addictions, and their consequences on health-related quality of life and socioeconomic parameters at baseline (cross-sectional part) and during the initial years of the psoriasis disease (longitudinal part).

NCT ID: NCT01961609 Completed - Psoriasis Clinical Trials

Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.

SIGNATURE
Start date: October 9, 2013
Phase: Phase 3
Study type: Interventional

This study was designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to anti-TNFα therapy in a United Kingdom (UK) and Republic of Ireland) specific population.

NCT ID: NCT01952015 Completed - Psoriasis Clinical Trials

Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Start date: August 21, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study was to assess efficacy and safety data of secukinumab in Japanese subjects with generalized pustular psoriasis (GPP). This study was expected to support the filing of secukinumab in the indication of pustular psoriasis in Japan.

NCT ID: NCT01947933 Completed - Psoriasis Clinical Trials

A Safety Study of Mirikizumab (LY3074828)

Start date: October 2013
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug and how the drug affects the body. The study will last about 3 months for each participant.

NCT ID: NCT01947491 Completed - Psoriasis Clinical Trials

A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis

Start date: November 2013
Phase: Phase 3
Study type: Interventional

The objectives of this study are to compare the safety of DFD01 Spray to Comp01 Lotion for topical treatment of moderate plaque psoriasis and to compare the efficacy of DFD01 Spray to Placebo Spray for topical treatment of moderate plaque psoriasis after 28 days of treatment.

NCT ID: NCT01946386 Completed - Psoriasis Vulgaris Clinical Trials

A Vasoconstriction Study With LEO 90100

Start date: September 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the pharmacodynamic activity of LEO 90100 with Dermovate® cream, Dovobet® ointment, betamethasone dipropionate in LEO90100 vehicle, Synalar® ointment and LEO 90100 vehicle using a human skin blanching test.

NCT ID: NCT01938599 Completed - Plaque Psoriasis Clinical Trials

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Start date: August 2013
Phase: Phase 2
Study type: Interventional

To compare the safety and efficacy profile of AM001 Cream and its vehicle in the treatment of plaque psoriasis.

NCT ID: NCT01937260 Completed - Psoriasis Clinical Trials

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

Start date: September 2013
Phase: Phase 1
Study type: Interventional

This is a phase 1, multi-center, open-label, drug-drug interaction (DDI) and PK study in subjects with moderate to severe plaque psoriasis. It is designed to evaluate the effect of brodalumab on midazolam PK in addition to assessing single dose PK of brodalumab in subjects with moderate to severe plaque psoriasis.

NCT ID: NCT01936337 Completed - Psoriasis Vulgaris Clinical Trials

Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients

Start date: August 2013
Phase: Phase 2
Study type: Interventional

In this study, the safety, tolerability and efficacy of DLX105 administered topically onto the psoriatic lesion of mild-to-moderate psoriasis patients will be investigated.